<DOC>
	<DOCNO>NCT01313221</DOCNO>
	<brief_summary>To estimate difference effectiveness treatment etanercept 50 mg twice weekly ( BIW ) treatment etanercept 50 mg weekly ( QW ) plus need ( PRN ) topical agent 12 week adults moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>The recommend starting dose etanercept adult plaque psoriasis patient 50 mg dose give twice week ( BIW ) 3 month follow reduction maintenance dose 50 mg weekly ( QW ) . While patient moderate severe plaque psoriasis manage satisfactorily etanercept monotherapy , proportion may require modified alternative treatment regimen ( eg , handle flare loss effect ) point chronic management . Despite clinical need , publish data randomize controlled study currently available demonstrate efficacy safety combine etanercept-based regimen patient plaque psoriasis . The addition as-needed topical medication step-down dose etanercept 50 mg weekly administer initial 12 week period 50 mg twice weekly may potential option patient may require adjunctive therapy . This study aim provide data treatment option estimate difference mean percent change Psoriasis Area Severity Index ( PASI ) score step-down etanercept 50 mg weekly supplement as-needed topical medication continuous treatment etanercept 50 mg twice weekly . Eligible patient enrol study receive etanercept 50 mg twice weekly 12 week . After 12 week etanercept treatment , participant randomize 1:1 ratio 1 2 treatment group .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Has stable moderate severe plaque psoriasis least 6 month ( eg , morphology change significant flare disease activity opinion investigator ) . Has body surface area ( BSA ) involvement ≥ 10 % Psoriasis Area Severity Index ( PASI ) ≥ 10 screen baseline . Is candidate systemic therapy phototherapy opinion investigator . Other inclusion criterion may apply . Has active guttate , erythrodermic , pustular psoriasis time screen visit . Has evidence skin condition time screen visit ( eg , eczema ) would interfere evaluation effect etanercept psoriasis . Diagnosed medicationinduced medicationexacerbated psoriasis . Significant concurrent medical condition . Has active localize infection ; require local intervention chronic localize infection . Other exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
	<keyword>etanercept</keyword>
	<keyword>Enbrel</keyword>
	<keyword>topical</keyword>
</DOC>